Senator Maggie Hassan raised concerns about recent news that the drug giant Novartis brokered a sweetheart deal with the Centers for Medicare and Medicaid Services (CMS) over an innovative new gene therapy which Novartis has priced at $475,000. The deal was halted after CMS’s own lawyers raised concerns, saying they were “surprised and concerned” with Novartis' influence on the process.